Sensitizing glioma cells to cisplatin by abrogating the p53 response with antisense oligonucleotides

Cancer Gene Therapy

Volumn 11, Issue 8, 2004, Pages 525-531

  Datta, Kamal ^a,b   Shah, Preeti ^a   Srivastava, Tapasya ^a   Mathur, Srinivas G ^a   Chattopadhyay, Parthaprasad ^a   Sinha, Subrata ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Antisense; Apoptosis; Chemotherapy; DNA damage; P53 independent

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CISPLATIN; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE G2 PHASE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DRUG MECHANISM; DRUG SENSITIVITY; GENE ACTIVITY; GENE THERAPY; GLIOMA CELL; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; G2 PHASE; GENES, P53; GLIOMA; HUMANS; MUTATION; OLIGORIBONUCLEOTIDES, ANTISENSE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 4043161200     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700724     Document Type: Article

References (48)

1. Ruley HE. p53 and response to chemotherapy and radiotherapy. In: DeVita VT, Hellman S, Rosenberg SA (eds) Important Advances in Oncology. Philadelphia, PA: JB Lippincott Co.; 1996:37-56.
2. Iwadate Y, Fujimoto S, Tagawa M, et al. Association of p53 gene mutation with decreased chemosensitivity in human malignant gliomas. Int J Cancer. 1996;69:236-240.
3. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB, Roth JA. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res. 1994;54:2287-2291.
4. Dorigo O, Turla ST, Lebedeva S, Gjerset RA. Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild-type p53 function. J Neurosurg. 1998;88:535-540.
5. Lotem J, Sachs L. Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood. 1993;82:1092-1096.
6. Aas T, Borresen AL, Geisler S, et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med. 1996;2:811-814.
7. Marks DI, Kurz BW, Link MP, et al. Altered expression of p53 and mdm-2 proteins at diagnosis is associated with early treatment failure in childhood acute lymphoblastic leukemia. J Clin Oncol. 1997;15:1158-1162.
8. Pollack IF, Finkelstein SD, Woods J, et al. Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med. 2002;346:420-427.
9. Badie B, Drazan KE, Kramar MH, Shaked A, Black KL. Adenovirus-mediated p53 gene delivery inhibits 9L glioma growth in rats. Neurol Res. 1995;17:209-216.
10. Gjerset RA, Turla ST, Sobol RE, et al. Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53. Mol Carcinogen. 1995;14:275-285.
11. Kock H, Harris MP, Anderson SC, et al. Adenovirus-mediated p53 gene transfer suppresses growth of human glioblastoma cells in vitro and in vivo. Int J Cancer. 1996;67:808-815.
12. Hsiao M, Tse V, Carmel J, et al. Intracavitary liposome-mediated p53 gene transfer into glioblastoma with endogenous wild-type p53 in vivo results in tumor suppression and long-term survival. Biochem Biophys Res Commun. 1997;233:359-364.
13. Burger H, Nooter K, Boersma AW, Kortland CJ, Stoter G. Lack of correlation between cisplatin-induced apoptosis, p53 status and expression of Bcl-2 family proteins in testicular germ cell tumour cell lines. Int J Cancer. 1997;73:592-599.
14. Haas-Kogan DA, Yount G, Haas M, et al. p53-dependent G1 arrest and p53-independent apoptosis influence the radiobiologic response of glioblastoma. Int J Radiat Oncol Biol Phys. 1996;36:95-103.
15. Malcomson RD, Oren M, Wyllie AH, Harrison DJ. p53-independent death and p53-induced protection against apoptosis in fibroblasts treated with chemotherapeutic drugs. Br J Cancer. 1995;72:952-957.
16. Makris A, Powles TJ, Dowsett M, Allred C. p53 protein overexpression and chemosensitivity in breast cancer. Lancet. 1995;345:1181-1182.
17. Mathieu MC, Koscielny S, Le Bihan ML, Spielmann M, Arriagada R. p53 protein overexpression and chemosensitivity in breast cancer. Institut Gustave-Roussy Breast Cancer Group. Lancet. 1995;345:1182.
18. Brachman DG, Beckett M, Graves D, Haraf D, Vokes E, Weichselbaum RR. p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res. 1993;53:3667-3669.
19. Bullock AN, Fersht AR. Rescuing the function of mutant p53. Nat Rev Cancer. 2001;1:68-76.
20. Leonard CJ, Canman CE, Kastan MB. The role of p53 in cell-cycle control and apoptosis: implications for cancer. In: De Vito V, Hallman S, Rosenberg S (eds) Important Advances in Oncology. Philadelphia, PA: JB Lippincot; 1995:33-42.
21. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science. 1994;266:1821-1828.
22. Koechli O, Schaer GN, Seifert B, et al. Mutant p53 protein associated with chemosensitivity in breast cancer specimens. Lancet. 1994;344:1647-1648.
23. Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 1993;85:200-206.
24. Fan S, Smith ML, Rivet 2nd DJ, et al. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res. 1995;55:1649-1654.
25. Hawkins DS, Demers GW, Galloway DA. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res. 1996;56:892-898.
26. Wu GS, El-Deiry WS. Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or bcl-2. Clin Cancer Res. 1996;2:623-633.
27. El-Mahdy MA, Hamada FM, Wani MA, Zhu Q, Wani AA. p53-degradation by HPV-16 E6 preferentially affects the removal of cyclobutane pyrimidine dimers from non-transcribed strand and sensitizes mammary epithelial cells to UV-irradiation. Mutat Res. 2000;459:135-145.
28. Chang FL, Lai MD. The relationship between p53 status and anticancer drugs-induced apoptosis in nine human bladder cancer cell lines. Anticancer Res. 2000;20:351-355.
29. Kandioler-Eckersberger D, Ludwig C, Rudas M, et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res. 2000;6:50-56.
30. Ogawa Y, Nishioka A, Inomata T, et al. Ionizing radiation-induced apoptosis in human lymphoma cell lines differing in p53 status. Int J Mol Med. 2000;5:139-143.
31. Poppenborg H, Knupfer MM, Preiss R, Wolff JE, Galla HJ. Cisplatin (CDDP)-induced radiation resistance is not associated with CDDP resistance in 86HG39 and A172 malignant glioma cells. Eur J Cancer. 1999;35:1150-1154.
32. Fulci G, Ishii N, Van Meir EG. p53 and brain tumors: from gene mutations to gene therapy. Brain Pathol. 1999;8:599-613.
33. Iwadate Y, Tagawa M, Fujimoto S, et al. Mutation of the p53 gene in human astrocytic tumours correlates with increased resistance to DNA-damaging agents but not to anti-microtubule anti-cancer agents. Br J Cancer. 1998;77:547-551.
34. Datta K, Babbar P, Srivastava T, Sinha S, Chattopadhyay P. p53 dependent apoptosis in glioma cell lines in response to hydrogen peroxide induced oxidative stress. Int J Biochem Cell Biol. 2002;34:148-157.
35. Lanza F, Bi S, Moretti S, Castoldi G, Goldman JM. Modulation of cell kinetics and cell cycle status by treating CD34+ chronic myeloid leukaemia cells with p53 antisense phosphorothioate oligonucleotides. Br J Haematol. 1995;90:8-14.
36. Kolfschoten GM, Hulscher TM, Schrier SM, van Houten VM, Pinedo HM, Boven E. Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin. Gynecol Oncol. 2002;84:404-412.
37. Kobayashi D, Tokino T, Watanabe N. Contribution of caspase-3 differs by p53 status in apoptosis induced by X-irradiation. Jpn J Cancer Res. 2001;92:475-481.
38. Shen Y, White E. p53-dependent apoptosis pathways. Adv Cancer Res. 2001;82:55-84.
39. Massey A, Offman J, Macpherson P, Karran P. DNA mismatch repair and acquired cisplatin resistance in E. coli and human ovarian carcinoma cells. DNA Repair (Amst). 2003;2:73-89.
40. Shelling AN. Role of p53 in drug resistance in ovarian cancer. Lancet. 1997;349:744-745.
41. Reles A, Wen WH, Schmider A, et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res. 2001;7:2984-2997.
42. Rusch V, Klimstra D, Venkatraman E, et al. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res. 1995;55:5038-5042.
43. Kastan MB, Zhan Q, el-Deiry WS, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 1992;71:587-597.
44. Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B. 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature. 1999;401:616-620.
45. Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene. 2001;20:1803-1815.
46. Serafin AM, Binder AB, Bohm L. Chemosensitivity of prostatic tumour cell lines under conditions of G2 block abrogation. Urol Res. 2001;29:221-227.
47. Binder AB, Serafin AM, Bohm LJ. Abrogation of G(2)/M-phase block enhances the cytotoxicity of daunorubicin, melphalan and cisplatin in TP53 mutant human tumor cells. Radiat Res. 2000;154:640-649.
48. Strunz AM, Peschke P, Waldeck W, Ehemann V, Kissel M, Debus J. Preferential radiosensitization in p53-mutated human tumour cell lines by pentoxifylline-mediated disruption of the G2/M checkpoint control. Int J Radiat Biol. 2002;78:721-732.